AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01720147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin (dietary supplement)
Description: Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above).
Study NCT00827047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hemihepatic vascular exclusion
Description: A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.
Study NCT00827047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemihepatic vascular Clamping
Description: Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.
Study NCT00827047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pringle's Maneuver
Description: Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
Study NCT01802671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioural therapy (CBT)
Description: Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~* Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~* Cognitive restructuring techniques~* Behavioural therapy and activity pacing~* Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions.
Study NCT01802671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behaviour therapy supported by ICT
Description: The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
Study NCT00807872 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 124I-labeled monoclonal antibody Mu 11-1F4
Description: Single infusion of radiolabeled antibody: 2 mCi (1 mg)
Study NCT00088153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic Estrogen/progesterone
Description: Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
Study NCT00088153 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
Study NCT02749929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser
Study NCT02749929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Level Laser Therapy
Description: The placebo laser is an identical device to the active laser, made by Irradia Midlaser
Study NCT02122276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle continuous passive motion machine.
Description: A rehabilitation program of machine driven passive stretch exercise on ankle.
Study NCT02128750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: contrast echographie with hexafluorur of sulfur
Description: Echography of contrast after injection of product of contrast (sonovue (r))
Study NCT04541654 — intervention group
Intervention type: GENETIC
Intervention: Data and Specimen Collection
Description: * Provide research team and access to relevant medical records~* Answer short questionnaires periodically~* Consider consenting to other optional parts of the research such as:~* Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional).~* Provide a saliva sample (optional).~* Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional).~* Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional).~* Consider inviting relatives to join the study (optional).
Study NCT02891824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab + avastin + platinum-based chemotherapy
Description: * atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles
Study NCT02891824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + avastin + platinum-based chemotherapy
Description: * placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles
Study NCT02555241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Equivalence Training
Description: The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
Study NCT04077398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
Study NCT02387918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
Study NCT02387918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
Study NCT03185351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of 0.5% bupivacaine using supraclavicular BPB.
Study NCT03185351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB
Study NCT03185351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.03 mg/kg of midazolam by I.V. route
Study NCT01779661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Aquatics
Description: Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
Study NCT01779661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Massage
Description: Infant Massage
Study NCT01509105 — intervention group
Intervention type: BIOLOGICAL
Intervention: 13-valent pneumococcal vaccine
Description: 0.5mL IM (Intramuscular administration) as per recommended schedule
Study NCT04058301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message information
Description: Geographically proximate resources delivered by text message
Study NCT03090269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Pill
Description: 3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
Study NCT01580748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500 microgram once daily for 16 weeks
Study NCT02558751 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
Study NCT02558751 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
Study NCT02340273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
Study NCT02340273 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo therapeutic ultrasound
Description: Patients receive sham therapeutic ultrasound daily for 4 hours.
Study NCT03608332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diaphragmatic ultrasound
Description: Diaphragmatic excursion; Diaphragmatic movement will be measured with a 3.5-MHz US probe (Mindray machine, DC-N6).
Study NCT01327703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panzytrat® 25,000
Description: Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
Study NCT01327703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kreon® 25,000
Description: Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
Study NCT02705157 — intervention group
Intervention type: PROCEDURE
Intervention: Stabilisation of (impending) pathological fracture
Description: Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
Study NCT02705157 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy of bone metastasis
Description: Radiotherapy of bone metastasis, single or multi-fractionated
Study NCT04124796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-structured interviews
Description: Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
Study NCT04124796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Description: Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
Study NCT00728923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPL-2003
Description: Minocycline (NPL-2003) daily for 12 weeks
Study NCT02129556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
Study NCT01910532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
Study NCT01150331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam/Clonazepam
Description: Association of two anti-epileptic drugs in first line
Study NCT01150331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam/Placebo levetiracetam IV
Description: Association of placebo to an active comparator (clonazepam)
Study NCT05538819 — intervention group
Intervention type: DRUG
Intervention: Glimepiride
Description: Glimepiride 1-4 mg/day
Study NCT04050917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real stimulation
Description: The smartwatch generates imperceptible vibratory stimulation.
Study NCT04050917 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: no stimulation
Description: The smartwatch generates no stimulation.
Study NCT03620656 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FibriCheck
Description: Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm
Study NCT04571515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-01
Description: Oral tablet
Study NCT04571515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study NCT00931840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZN-2208, Cetuximab and Irinotecan
Description: Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C).
Study NCT02891330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and nutritional recommendations conducted by a nurse
Description: Supplementary dietary and nutritional education
Study NCT00931840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EZN-2208, Cetuximab and Irinotecan
Description: Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C).
Study NCT03798899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: PENTHROX 3mL inhalation vapour, liquid
Study NCT03798899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo
Study NCT04161456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast twice daily 30 mg
Study NCT04403633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile health educational tool
Description: Interactive educational tool delivered on iPad
Study NCT01419444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Airflow Exercises for Voicing
Description: Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
Study NCT01419444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Airflow Exercises for Voicing
Description: Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
Study NCT01742676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAGRAF
Description: oral
Study NCT01742676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROGRAF
Description: oral
Study NCT04445974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expand your horizons: More than my skin
Description: 'Expand Your Horizon' is a self-help intervention which uses writing exercises to help individuals with poor body image practice focusing on their body-functionality rather than their physical appearance (Alleva et al., 2015). The materials for 'Expand Your Horizon' are freely available (Alleva et al., 2015), and permission has been granted to use and adapt the materials in this research. 'Expand Your Horizon' comprises of three 15 min writing exercises, typically completed over approximately six days. The intervention materials have been adapted for use with a population with skin diseases, and modified to use gender neutral language. Adaptions were made in consultation with experts by experience. The changes were reviewed and approved by the first author of the original intervention to ensure the materials were in keeping with the original intervention.
Study NCT04445974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creative writing activities
Description: In line with previous studies examining 'Expand Your Horizon' the active control condition will involve creative writing tasks (Alleva et al., 2015). Participants in the intervention condition will complete three 15 minute creative writing exercises, completed over six days.
Study NCT00433537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT04215003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A
Description: Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle. Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle,6 cycles.~Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle,6 cycles.
Study NCT04215003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B
Description: Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.
Study NCT04215003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL4
Description: SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off); oral letrozole 2.5 mg daily； Adebrelimab was given intravenously, 600mg each time, once every 2 weeks; Premenopause：Goserelin 3.6mg IM IM Q4W.
Study NCT01137591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APAP and NAC combination
Description: APAP 650mg and NAC 600mg combination oral tablet administered once
Study NCT01137591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APAP and Placebo
Description: APAP 650mg and Placebo combination oral tablet administered once
Study NCT03026374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be Resilient to Breast Cancer
Description: This is a supportive-expressive group therapy.
Study NCT01658774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Single 400mg dose
Study NCT01658774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Single 400mg dose
Study NCT01658774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 500 mg Vitamin C
Study NCT04024007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Citrate dosage
Description: Patients are dialysed according to the standard of care. Biological variables are measured in pre-filter, post-filter and dialysate 30 minutes after the dialysis is initiated.
Study NCT03133533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic repair
Description: Surgical inguinal hernia repair using laparoscopic approach.